問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

5272Cases

2022-10-01 - 2026-01-16

Phase III

An Interventional Efficacy and Safety Phase 3 Double-blind 2-arm Study to Investigate IV Followed by Oral Fosmanogepix Compared With IV Caspofungin Followed by Oral Fluconazole in Adult Participants With Candidemia and/or Invasive Candidiasis

  • Condition/Disease

    Adult patients with candidemia and/or invasive candidiasis

  • Test Drug

    Fosmanogepix CANCIDAS Fosmanogepix Caspofungin Fluconazole

Participate Sites
2Sites

Recruiting2Sites

2021-05-01 - 2023-10-30

Phase II

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants With Pulmonary Fibrosis

  • Condition/Disease

    Pulmonary Fibrosis

  • Test Drug

    BMS-986278

Participate Sites
3Sites

Recruiting3Sites

2023-12-15 - 2028-06-30

Phase III

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Amyloid Depleter ALXN2220 in Adult Participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

  • Condition/Disease

    Transthyretin amyloid cardiomyopathy

  • Test Drug

    ALXN2220

Participate Sites
5Sites

Recruiting5Sites

2022-12-14 - 2026-01-01

Phase III

Active
A multi-center, randomized, double-blind, active-controlled, therapeutic confirmatory, phase III study to compare and evaluate the efficacy and safety of Epaminurad with Febuxostat in gout patients

  • Condition/Disease

    gout

  • Test Drug

    Epaminurad

Participate Sites
13Sites

Not yet recruiting1Sites

Recruiting12Sites

2024-04-30 - 2024-09-12

Phase II

A Phase 2a, Open-Label Multiple Dose Study Evaluating the Safety, Tolerability, and Pharmacodynamics of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab, a PD-L1 Monoclonal Antibody, in Subjects With Chronic HBV Infection

  • Condition/Disease

    Hepatitis B, Chronic

  • Test Drug

    AB-729

Participate Sites
5Sites

Terminated5Sites

2023-09-29 - 2025-01-16

Phase III

A multicenter, randomized, prospective double-blind, cross-over Phase 3 study to evaluate the efficacy and safety of 0.04 mmol Gd/kg body weight of gadoquatrane for MRI in adults with known or suspected pathology of any body region (except CNS), compared to 0.1 mmol Gd/kg approved macrocyclic gadolinium-based contrast agents (GBCAs)

  • Condition/Disease

    Contrast-enhanced MRI is used to assess known or suspected pathology in body sites.

  • Test Drug

    Gadoquatrane (BAY 1747846) Dotarem (Gadoteric acid)

Participate Sites
4Sites

Not yet recruiting2Sites

Recruiting1Sites

Terminated1Sites

2023-04-01 - 2030-12-31

Phase III

Active
A Phase III, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Versus Alpelisib Plus Fulvestrant in Patients With Hormone Receptor-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Who Progressed During or After CDK4/6 Inhibitor and Endocrine Combination Therapy

  • Condition/Disease

    Breast Cancer

  • Test Drug

    GDC-0077(Inavolisib)Alpelisib(Piqray)Fulvestrant (Faslodex)

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

2023-09-01 - 2023-09-01

Phase I

A phase 1 clinical trial evaluating the safety and immunogenicity of OBI-BCVax in the prevention of COVID-19 in healthy adults.

  • Condition/Disease

    Prevention of COVID-19 infection in healthy adults

  • Test Drug

    OBI-BCVax

Participate Sites
1Sites

Not yet recruiting1Sites

2024-07-01 - 2027-12-31

Phase III

Active
Studies of Heart & Kidney Protection with BI 690517 in combination with empagliflozin: A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease

  • Condition/Disease

    chronic kidney disease

  • Test Drug

    placebo ‧ BI 690517 Empagliflozin

Participate Sites
23Sites

Recruiting23Sites

2016-03-01 - 2023-09-01

Phase III

An open-label, randomized, controlled phase III trial evaluating the efficacy and safety of EndoTAG-1 in combination with paclitaxel and gemcitabine compared to paclitaxel and gemcitabine as first-line therapy in patients with visceral metastatic triple-negative breast cancer

  • Condition/Disease

    visceral metastatic triple-negative breast cancer

  • Test Drug

    EndoTAG-1

Participate Sites
3Sites

Recruiting3Sites

1 297 298 299 300 301 528
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB